Event Participants
Executives
4
Ankit Jain (Head of Investor Relations), Sahil Maheshwari (Head of Strategy), Sandeep Jain (Co-Founder & Managing Director), Sumeet Sood (Chief Financial Officer)
Analysts
8
Abdulkader Puranwala (ICICI Securities), Akshay Shah (VVD Asset Managers), Anchal Maheshwari (Naredi Investments), Bhavin R. Chheda (Enam Holdings), Divya Daga (VGSPL), Praveen Jayaraman (Avendus Spark Institutional Equities), Sangeeta Purushottam (Cogito Advisors), Vivek Agarwal (Citigroup Global Markets India)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Operating Revenue | ₹1,167 crores | +13.9% YoY vs ₹1,024 crores; +0.8% QoQ vs ₹1,158 crores. Growth led by CDMO segment with double-digit volume growth and improving API prices. |
| Operating EBITDA | ₹175 crores (15% margin) | +35.4% YoY vs ₹129 crores; +15.1% QoQ vs ₹150 crores. Margin expanded 230 bps YoY (from 12.6%) and 187 bps QoQ (from 13.1%), aided by improved capacity utilization and higher non-CEFA API product mix. |
| EBITDA incl. Other Income | ₹205 crores (17.1% margin) | +31.7% YoY vs ₹156 crores; +9.6% QoQ vs ₹187 crores. Margin expanded 231 bps YoY (from 14.8%). |
| PAT | ₹101 crores | +56.1% YoY vs ₹64.65 crores; +24.1% QoQ vs ₹81 crores. Strong margin performance flowed through to bottom line. |
| CDMO Revenue | ₹964 crores | +18.6% YoY vs ₹813 crores; +1.3% QoQ vs ₹952 crores. Driven by healthy high-teens volume growth and rebound in API prices (Q2 trend). |
| CDMO EBITDA | ₹163 crores (16.9% margin) | +36.8% YoY vs ₹119 crores; +19% QoQ vs ₹137 crores. Margin aided by improved capacity utilization and strategic inventory builds. |
| Domestic Branded (Acumentis) Revenue | ₹115 crores | +7.3% YoY vs ₹107 crores; +12.9% QoQ vs ₹102 crores. Growth from mix of new launches, price growth, and volume. |
| Acumentis EBITDA | ₹12 crores | -25.4% YoY vs ₹16 crores; -46.5% QoQ vs ₹22.4 crores. Margin impacted by ~200 new field force hires (15% increase in field force). |
| International Branded (UniSource) Revenue | ₹35 crores | -1.5% YoY vs ₹35.5 crores; -3.6% QoQ vs ₹36.5 crores. Muted quarter; growth expected to return Q2-Q3 onwards. |
| UniSource EBITDA | ₹6.9 crores | -14.4% YoY vs ₹8 crores; -31% QoQ vs ₹10 crores. |
| API Revenue | ₹32 crores | -29.7% YoY vs ₹45.5 crores; -22.3% QoQ vs ₹41.2 crores. Revenue decline due to strategic shift from CEFA to non-CEFA products. |
| API EBITDA | -₹4 crores | Losses narrowed from -₹6 crores (Q1 FY26) and -₹12 crores (Q4 FY26). Higher share of non-CEFA products (Linezolid, Montelukast) improving gross margins. |
| Trade Generics Revenue | ₹21 crores | -9.5% YoY vs ₹23.2 crores; -23.4% QoQ vs ₹27.4 crores. |
| Trade Generics EBITDA | ₹0.1 crores | Breakeven for second consecutive quarter, vs -₹5 crores (Q1 FY26) and ₹1.1 crores (Q4 FY26). |
| Cash Surplus | ₹1,616 crores | 98% parked in fixed deposits with nationalized banks. Net worth exceeds ₹3,400 crores; balance sheet deleveraged. |
| Operating Cash Flow | ₹65 crores | Q1 FY27. |
Geographic & Segment Commentary
CDMO: Core growth engine delivering +18.6% YoY revenue growth with high-teens volume growth for Q3/Q4 FY26 and Q1 FY27. API price environment is volatile but trending upward, supporting value growth. Management confirmed cost-plus pricing model passes input costs through; Q2 FY27 volume outlook remains strong at high-teens. Gross margins well over 40%; strategic inventory builds in Q4 FY26 protected Q1 margins. Margins guided at 14-15% annually, with FY27 expected to incline toward upper bracket.
Acumentis (Domestic Branded): Grew 7.3% YoY with growth driven by new product launches, price increases, and volume. Added
200 field force personnel (15% increase) targeting adjacent headquarters cities; this investment drove EBITDA decline of 25.4% YoY. Focus therapies remain gynecology, cardiology, pediatrics, with orthopedics and derma following. Management expects improved performance from Q3 FY27 as new hires generate prescriptions per call per month (PCPM). Strategy is long-term: build clinical presence, then scale profitability to industry averages.UniSource (International Branded): Muted quarter with revenue flat at ₹35 crores and EBITDA declining 14.4% YoY to ₹6.9 crores. Company present in 60+ geographies with focus markets identified for deeper penetration. Strategy involves filing niche "first-to-launch" products in select markets to build sticky, high-margin businesses. Management expects growth to return in Q2-Q3 FY27 with pipeline of new product registrations.
API: Revenue declined 29.7% YoY to ₹32 crores, but EBITDA losses narrowed to -₹4 crores from -₹6 crores (Q1 FY26) and -₹12 crores (Q4 FY26). Strategic pivot from low-margin CEFA products to non-CEFA products (Linezolid, Montelukast) improving gross margin profile. Management confirmed target of monthly EBITDA breakeven by February-March FY27 and positive contribution to corporate from FY28.
Trade Generics: Revenue declined 9.5% YoY to ₹21 crores, but segment remained EBITDA breakeven (₹0.1 crores) for second consecutive quarter. Zambia order (US$25 million) expected to reflect during FY27, likely H2, which will drive revenue uplift.
Company-Specific & Strategic Commentary
Oriflame Acquisition: Announced July 23, 2026 - acquisition of Oriflame India's manufacturing business comprising two facilities (Roorkee, Uttarakhand and Noida, Uttar Pradesh) plus leased warehouse in Noida. Strategic rationale: expand into skincare, cosmetics, and wellness manufacturing; enable entry into fast-growing color cosmetics segment. Complements existing dedicated cosmetics facility (Plant 5) which is at peak utilization and has good profitability. Positions Akums to serve the rapidly growing beauty and personal care (BPC) market.
Capacity Expansion: Baddi facility under construction for oral solid dosage manufacturing, expected to go live by end of FY27. Current capacity utilization at ~50%, with peak utilization potential of 55-58-60%. Strategy remains maintaining spare capacity to capture market opportunities, as demonstrated by high-teens volume growth in recent quarters. No subcontracting of low-margin orders; gross margins well over 40% with basket approach to client relationships.
Zambia Government Supply Order: US$25 million order (~₹240 crores revenue) expected to deliver in H2 FY27 with similar quantum in FY28. Advanced stages - volumes and prices agreed on 100+ products with Zambian government. Margin profile expected in high-teens, higher than core CDMO business.
European Business: Expected to kick-start in FY28; margins guided at high-teens (15-17%), elevating corporate margins. Represents next growth frontier alongside Zambia.
Field Force Expansion: ~200 new hires in Acumentis (15% increase) targeting adjacent headquarters cities. Investment is near-term EBITDA drag with expected payback from Q3 FY27 onwards.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth (CDMO) | High-teens volume growth continuing | Q2 FY27 volumes tracked at high-teens; API prices volatile but moving upward. Full-year volume growth expected at least double digits. |
| EBITDA Margin (Operating) | 14-15% for FY27 | Q1 FY27 delivered 15%; management expects to incline toward upper bracket given strong Q1. Cost-plus model protects against API price inflation. |
| EBITDA Margins (Zambia & Europe) | High-teens (15-17%) | Both businesses expected to deliver margins above core CDMO, uplifting corporate margins. Zambia in H2 FY27; Europe from FY28. |
| Acumentis Performance | Improved from Q3 FY27 | Field force productivity expected to generate returns from Q3; continued expansion into prescription business. |
| UniSource Growth | Return to growth from Q2-Q3 FY27 | Niche product filings and focused market strategy expected to drive recovery. |
| API Segment | Monthly EBITDA breakeven by Feb-Mar FY27 | Non-CEFA product mix shift driving margin improvement; segment to positively contribute from FY28. |
| Baddi Facility | Go-live by end of FY27 | New oral solid dosage facility to support sustained volume growth. |
| Zambia Order | US$25 million (~₹240 crores) in H2 FY27 | Volumes and prices agreed on 100+ products; similar quantum expected FY28. |
| FY27 Overall | Robust operating performance expected | Management confident of delivering strong full-year operating results. |
Risks & Constraints
| Risk | Context |
|---|---|
| API Price Volatility | API prices currently volatile but trending upward. While cost-plus model passes through input costs, sustained inflation could impact client ordering behavior or inventory decisions. Management notes clients already adjusted to 5-6 months of elevated prices with volume growth continuing. |
| Branded Formulation Execution | Acumentis EBITDA declined 25.4% YoY due to field force expansion; UniSource revenue flat. If new field hires take longer to generate prescriptions, or UniSource product registrations face delays, near-term profitability in these segments could lag. Management expects improvement from Q3 FY27. |
| Zambia/Europe Execution Dependency | Revenue recognition from Zambia (H2 FY27) and Europe (FY28) carries execution risk - regulatory approvals, timelines, and geopolitical factors could delay revenue recognition. These orders are expected to materially uplift corporate margins. |
| Oriflame Acquisition Integration | Integration of two manufacturing facilities plus warehouse carries operational risks. If integration takes longer than anticipated, expected synergies in skincare/cosmetics expansion could be delayed. Financial details not yet disclosed. |
| Capacity Betting | Strategy of maintaining substantial spare capacity (currently ~50% utilization vs 55-60% peak) ties up capital. While enabling rapid scaling for volume opportunities, lower utilization could pressure fixed-cost absorption if volume growth disappoints. |
Q&A Highlights
CDMO Growth and Margins
- Question: Can you highlight CDMO growth outlook for volume/value and margin trajectory? (Vivek Agarwal, Citigroup)
- Answer: Q2 volumes tracking in high-teens; API prices volatile but moving upward, supporting value growth. Margins expected to remain in 14-15% band annually; given strong Q1, incline toward upper bracket. Q4 FY26 strategic inventory builds protected Q1 margins. (Sahil Maheshwari)
Branded Formulation Strategy
- Question: What's driving growth and margin pressure in domestic/international branded segments? (Vivek Agarwal, Citigroup)
- Answer: Acumentis added
200 field force personnel (15% increase) to tap adjacent headquarters cities; near-term PCPM drag on EBITDA. Focus on gynecology, cardiology, pediatrics. UniSource had one muted quarter; Q2-Q3 onwards growth returns. Niche first-to-launch product filings in select markets will build sticky high-margin businesses. (Sahil Maheshwari)
API Business Commitment
- Question: Is there a timeframe to evaluate whether to continue with the API business? (Sangeeta Purushottam, Cogito Advisors)
- Answer: Management fully confident and committed to API business after 3-4 years of investment; quarterly losses gradually declining. Shift from low-margin CEFA to non-CEFA products (Linezolid, Montelukast) improving margins. It's not about whether to exit but how to scale into profitable venture. (Sahil Maheshwari)
- Follow-up: As a minority shareholder, I'd prefer you exit API and focus on CDMO/exports. (Sangeeta Purushottam)
- Response: Management acts in best interest of all shareholders; capital allocation and bandwidth decisions taken for long-term value creation. (Sahil Maheshwari)
Zambia and Europe Margin Guidance
- Question: Any updated margin guidance for Zambia and Europe? (Sangeeta Purushottam, Cogito Advisors)
- Answer: Both Zambia and Europe margins expected in high-teens (15-17% range), tad higher than current CDMO business. Zambia US$25 million order (~₹240 crores) expected to deliver in H2 FY27 with similar quantum next fiscal year. European business kicks off in FY28; both will uplift corporate margins. (Sahil Maheshwari)
Capacity Utilization Strategy
- Question: Will you continue spare capacity strategy or optimize? (Sangeeta Purushottam, Cogito Advisors)
- Answer: Strategy remains maintaining spare capacity - Q3 FY26 sudden 20% volume growth was captured due to this preparedness. Current utilization ~50% vs peak potential of 55-58-60%. In process of expanding further; Baddi facility going live end of FY27 to boost oral manufacturing. No subcontracting concept - basket approach with clients. (Sahil Maheshwari)
Oriflame Acquisition Rationale
- Question: Is the Oriflame acquisition capability or capacity driven? (Praveen Jayaraman, Avendus Spark)
- Answer: Acquisition expands capacity in skincare/cosmetics manufacturing - existing cosmetics plant (Plant 5) is at peak utilization with good profitability. Enables entry into color cosmetics, a fast-growing space. Strong formulation R&D base at Akums will be leveraged to tap additional niche markets within cosmeceuticals. BPC market growing rapidly; adds meaning to top line and bottom line. (Sahil Maheshwari)
Gross Margin Sustainability
- Question: How much of gross margin improvement is value addition vs inventory gains? (Akshay Shah, VVD Asset Managers)
- Answer: Very limited inventory gains - most improvement from high-value products. API gross margins improved from ~90%+ to ~75% gross loss (loss reduction). Gross margin sustainability expected; CDMO remains torchbearer. (Sahil Maheshwari)
API Profitability Timeline
- Question: Is the API segment still on track to turn profitable by end of FY27? (Abdulkader Puranwala, ICICI Securities)
- Answer: Target is monthly EBITDA positive by February-March FY27; next year (FY28) segment starts positively contributing to corporate. Losses narrowing consistently - no seasonality, fully in control. (Sahil Maheshwari)
Balance Sheet and Capital Allocation
- Question: Where is ₹1,616 crores of cash parked and how will it be deployed? (Abdulkader Puranwala, ICICI Securities)
- Answer: 98% parked in fixed deposits with nationalized banks - safe and secure. Net worth above ₹3,400 crores with no debt. Company has appetite for acquisitions if synergistic and value-accretive. Continually exploring opportunities; will announce when appropriate. (Sumeet Sood)
Field Force Productivity
- Question: Field force productivity is lower than industry - why expand? (Akshay Shah, VVD Asset Managers)
- Answer: PCPM is outcome of a mature marketing business; Acumentis is still in building phase. Expansion targets additional geographies and headquarters cities for focus therapy products. As business scales, productivity will inch toward industry averages. Cautious approach to investments in features and products. (Sahil Maheshwari)
Key Takeaway
Akums Drugs delivered a strong Q1 FY27 with operating revenue of ₹1,167 crores (+13.9% YoY) and EBITDA of ₹175 crores (+35.4% YoY, 15% margin), driven by CDMO high-teens volume growth, improving API prices, and strategic inventory builds. PAT grew 56.1% YoY to ₹101 crores, with cash surplus at ₹1,616 crores and zero debt. Strategic initiatives include the Oriflame India acquisition for skincare/cosmetics expansion, Baddi capacity addition going live by end of FY27, and continued investment in Acumentis field force (200 hires) expected to pay off from Q3. Management guided operating EBITDA margins at 14-15% for FY27 with inclination toward upper bracket, Zambia US$25 million order (₹240 crores) recognized in H2 FY27, and API segment reaching monthly EBITDA breakeven by Feb-Mar FY27. Europe business kicks off FY28 with high-teens margins. Key watch points include API price volatility, branded formulation margin recovery timeline, and execution of Zambia/Europe revenue recognition.